உயிரியல் உளவுத்துறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உயிரியல் உளவுத்துறை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உயிரியல் உளவுத்துறை Today - Breaking & Trending Today

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms

Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

John Reuter , Bob Chen , Gilead Sciences , Ligand Pharmaceuticals , Ligand Pharmaceuticals Incorporated , Baxter International , Expression Technology , Systems Engineering , Vice President , Biological Intelligence , Google Brain , ஜான் ராய்டர் , பாப் சென் , கிலியட் அறிவியல் , பாக்ஸ்டர் சர்வதேச , வெளிப்பாடு தொழில்நுட்பம் , அமைப்புகள் பொறியியல் , துணை ப்ரெஸிடெஂட் , உயிரியல் உளவுத்துறை , கூகிள் மூளை ,

Ligand Reports First Quarter 2021 Financial Results

Ligand Reports First Quarter 2021 Financial Results
Search jobs
Conference Call Begins at 4:30 p.m. Eastern Time Today
SAN DIEGO (BUSINESS WIRE) $LGND#earnings
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
“This year has opened strong for Ligand with solid financial performance and great results from all of our core technology platforms,” said John Higgins, Chief Executive Officer. “We are very pleased to report a smooth and efficient integration of the four acquisitions we closed last year. Our R&D team has expanded considerably and we are reaping the benefits of these transactions with more licensing deals and contract revenue. Working within a highly dynamic and unpredictable COVI ....

John Higgins , Valentino Stella , Jay Gertz , Bruce Voss , Acrotech Biopharma , Baxter International , Jazz Pharmaceuticals , University Of Utah , Pelican Expression Technology , Serum Institute Of India , Cstone Pharmaceuticals , Gilead Sciences , Ligand Pharmaceuticals , Ligand Pharmaceuticals Incorporated , Huntsman Cancer Institute , European Commission , Drug Administration , University Distinguished Professor , Ligand Protein Expression Technology , University Of Kansa Higuchi Biosciences Center , Sermonix Pharmaceuticals , European Medicines Agency , Conference Call Begins , Chief Executive , Recent Business Highlights , Biological Intelligence ,

Ligand Pharmaceuticals Inc (LGND) Q4 2020 Earnings Call Transcript

Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Ligand Pharmaceuticals Q4 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Patrick O Brien. Thank you. Please go ahead.
Patrick O Brien
Investor Relations
Thank you, Brandy. And welcome to Ligand s fourth quarter of 2020 financial results and business update conference call. All of our speakers for today s call are in separate locations. Speaking today for Ligand will be John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO. We will use non-GAAP financial measures and some of our statements will be forward-looking. Additional information concerning risk factors and other matters concerning Ligand can be found in our Ligand s earning press release and our periodic filings with the SEC. Ligand undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this confe ....

United States , Matt Hewitt , Patrick Obrien , Matt Foehr , Matthew Foehr , Matt Korenberg , Balaji Prasad Barclays , John Higgins , Joe Pantginis , Balaji Prasad , Scott Henry , Dana Flanders , Matt Hewitt Craig Hallum Capital Group Analyst , Ligand Pharmaceuticals , Ligand Pharmaceuticals Inc , Jazz Pharmaceuticals , Cystic Fibrosis Foundation , Dana Flanders Guggenheim Securities , Stanford University , Joseph Pantginis Hc Wainwright Co , Vice President , Chief Financial , Analyst Day , Chief Operating , Antibody Discovery Tech , Biological Intelligence ,